Literature DB >> 3024973

Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.

M P Cranage, T Kouzarides, A T Bankier, S Satchwell, K Weston, P Tomlinson, B Barrell, H Hart, S E Bell, A C Minson.   

Abstract

A human cytomegalovirus (HCMV) glycoprotein gene with homology to glycoprotein B (gB) of herpes simplex virus and Epstein-Barr virus and gpII of varicella zoster virus has been identified by nucleotide sequencing. The gene has been expressed in recombinant vaccinia virus and the gene product recognized by monoclonal antibodies and human immune sera. Rabbits immunized with the recombinant vaccinia virus produced antibodies that immunoprecipitate gB from HCMV-infected cells and neutralize HCMV infectivity in vitro. These data demonstrate a role for this protein in future HCMV vaccines.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3024973      PMCID： PMC1167261          DOI： 10.1002/j.1460-2075.1986.tb04606.x

Source DB:  PubMed          Journal:  EMBO J        ISSN： 0261-4189            Impact factor:   11.598


  36 in total

1.  Plasmodium knowlesi sporozoite antigen: expression by infectious recombinant vaccinia virus.

Authors:  G L Smith; G N Godson; V Nussenzweig; R S Nussenzweig; J Barnwell; B Moss
Journal:  Science       Date:  1984-04-27       Impact factor: 47.728

2.  Graphic methods to determine the function of nucleic acid sequences.

Authors:  R Staden
Journal:  Nucleic Acids Res       Date:  1984-01-11       Impact factor: 16.971

3.  Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins.

Authors:  B Nowak; C Sullivan; P Sarnow; R Thomas; F Bricout; J C Nicolas; B Fleckenstein; A J Levine
Journal:  Virology       Date:  1984-01-30       Impact factor: 3.616

4.  Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

Authors:  G L Smith; M Mackett; B Moss
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

5.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

6.  Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.

Authors:  E Paoletti; B R Lipinskas; C Samsonoff; S Mercer; D Panicali
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

Review 7.  Cytomegalovirus infections following renal transplantation.

Authors:  J Glenn
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

8.  Electrophoretic analysis of polypeptides immune precipitated from cytomegalovirus-infected cell extracts by human sera.

Authors:  L Pereira; M Hoffman; N Cremer
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

9.  Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters.

Authors:  G L Smith; B R Murphy; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

10.  Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin.

Authors:  D Panicali; S W Davis; R L Weinberg; E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1983-09       Impact factor: 11.205
View more
  129 in total

1.  An acidic cluster in the cytosolic domain of human cytomegalovirus glycoprotein B is a signal for endocytosis from the plasma membrane.

Authors:  S Tugizov; E Maidji; J Xiao; L Pereira
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Distinct glycoprotein O complexes arise in a post-Golgi compartment of cytomegalovirus-infected cells.

Authors:  Regan N Theiler; Teresa Compton
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

Authors:  B Wagner; B Kropff; H Kalbacher; W Britt; V A Sundqvist; L Ostberg; M Mach
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Functional analysis of the true late human cytomegalovirus pp28 upstream promoter: cis-acting elements and viral trans-acting proteins necessary for promoter activation.

Authors:  A S Depto; R M Stenberg
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

5.  Identification and characterization of three distinct families of glycoprotein complexes in the envelopes of human cytomegalovirus.

Authors:  D R Gretch; B Kari; L Rasmussen; R C Gehrz; M F Stinski
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

6.  Glycoprotein B of bovine herpesvirus type 4: its phylogenetic relationship to gB equivalents of the herpesviruses.

Authors:  M Goltz; H Broll; A Mankertz; W Weigelt; H Ludwig; H J Buhk; K Borchers
Journal:  Virus Genes       Date:  1994-09       Impact factor: 2.332

7.  Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals.

Authors:  P X Guo; S Goebel; S Davis; M E Perkus; B Languet; P Desmettre; G Allen; E Paoletti
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

8.  Postoligomerization folding of human cytomegalovirus glycoprotein B: identification of folding intermediates and importance of disulfide bonding.

Authors:  M A Billstrom; W J Britt
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  Spliced transcripts of human cytomegalovirus.

Authors:  W D Rawlinson; B G Barrell
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

10.  Human cytomegalovirus glycoproteins gB and gH/gL mediate epithelial cell-cell fusion when expressed either in cis or in trans.

Authors:  Adam L Vanarsdall; Brent J Ryckman; Marie C Chase; David C Johnson
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.